Results 361 to 370 of about 1,881,376 (382)

Neutralizing antibodies to interferon

Neurology, 2007
The impact of neutralizing antibodies (NAbs) to interferon-beta (IFN-beta) on clinical and imaging parameters in multiple sclerosis (MS) is reviewed. An effect on relapse rates and imaging parameters was noted in patients who tested positive for NAbs, but disability measures were unaffected or showed a trend toward improvement.
openaire   +2 more sources

Neutralizing antibody in nonallergic individuals

Journal of Allergy, 1952
Abstract Neutralizing antibody titrations were carried out in series of nonatopic human volunteers receiving one of the following ragweed preparations: (1) aqueous, (2) dialyzed aqueous, (3) alum precipitated, and (4) tannic acid precipitated extract. Also, extracts were made up to contain one of the following: (5) 10 per cent polyvinylpyrrolidone, (6)
S, MALKIEL, S M, FEINBERG
openaire   +2 more sources

Production of Neutralizing Antibody

Techniques employing monoclonal antibodies (mAbs) are widely used in the initial development phase of biologics. The usefulness of mAbs in basic RA research has been established based on their characteristics, including specificity of binding, homogeneity, and ability to be produced on a large scale.
Erika, Takemasa, Shuang, Liu
openaire   +2 more sources

Testing for neutralizing antibodies

British Journal of Neuroscience Nursing, 2007
Interferon-beta drugs for multiple sclerosis sometimes give rise to immune proteins that neutralize their effects. Nicola O'Connell and Bronwen Roper look at testing for these neutralizing antibodies
Nicola O'Connell, Bronwen Roper
openaire   +1 more source

Statistical issues in neutralizing antibodies

Neurology, 2003
Frequently the question of the effects of neutralizing antibodies (NAbs) is stated, but not clearly. Some ask: “Are we sure NAbs are important?” And others ask: “Are we sure NAbs are NOT important?” These two questions can lead to different statistical designs and different approaches to the investigation of the impact of NAbs.
openaire   +2 more sources

Neutralization of HIV by Antibodies

2008
Antibodies can neutralize HIV-1 with potency and cross-reactivity that varies widely and is related but not correlated to their antigen-binding affinity. Therefore, in addition to measuring binding affinity, an evaluation of the antibody neutralizing activity in tissue cultures is important for development of antibody-based therapeutics, design of ...
Ilia, Prado, Timothy R, Fouts, Antony S, Dimitrov   +2 more
openaire   +2 more sources

Sensitive neutralization test for virus antibody

Archives of Virology, 1978
A sensitive mumps virus plaque neutralization test has been developed based on the potentiation of virus-antibody complexes by heterologous anti-immunoglobulins (AIG). The enhanced neutralization test was approximately 100 times more sensitive than the conventional neutralization test or the hemagglutination-inhibition test.
H, Sato, P, Albrecht, J T, Hicks, B C, Meyer, F A, Ennis   +4 more
openaire   +2 more sources

Neutralization of Arenaviruses by Antibody

1987
Neutralization of infectivity is the end result of a number of alternative or synergistic reactions between a virus and antibody directed against certain antigenic determinants on its surface. These reactions prevent either the attachment of virus to a particular host cell by steric hindrance, the entry of virus into the cell, or the uncoating of the ...
openaire   +2 more sources

Standardization of Poliovirus Neutralizing Antibody Tests

Clinical Infectious Diseases, 1984
Recently the Forum for Advancement of Immunization Research sponsored a Collaborative Study on Poliovirus Antibody Titration. Twenty laboratories from 12 countries participated. There were considerable differences in detail of test performance and test results among laboratories.
P, Albrecht, G, van Steenis, A L, van Wezel, J, Salk   +3 more
openaire   +2 more sources

Cytokine-neutralizing therapeutic antibodies

2000
Monoclonal antibodies (Mabs) offer the potential as useful therapeutic agents because of their high affinity and selectivity for the target antigen. The standard approach in making Mabs has been to immunise rodents, usually mice, with the desired human protein and generate a mouse anti-human IgG through hybridoma technology.
Amanda Suitters, Roly Foulkes
openaire   +1 more source